Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Metastatic Breast Cancer
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
- Trial name
- NCT01937507
- Testing
- HAI with FOLFOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Western Regional Medical Center
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00459108
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery.
- Trial name
- NCT01004978
- Testing
- Cisplatin, Computed Tomography, Doxorubicin Hydrochloride
- Where
- 281 sites in United States
- Volunteers
- 235 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
The Exalenz clinical investigation is a multicenter, non-randomized, study of the ¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to evaluate the capability of the OBT measurement to…
- Trial name
- OBT for HCC (NCT01433016)
- Testing
- 13C Sodium Octanoate
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Meridian Bioscience, Inc.
Hepatocellular Carcinoma
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized…
- Trial name
- OPTIMA (NCT02112656)
- Testing
- ThermoDox, Dummy infusion
- Where
- 61 sites in United States, Canada and 12 more
- Volunteers
- 554 people
- Sponsor
- Imunon
Hepatocellular Carcinoma, HCC
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness…
- Trial name
- NCT01871545
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma, Liver Cancer
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT00242502
- Testing
- Bevacizumab (Avastin), Erlotinib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
The purpose of this study is to compare the overall survival (OS) for Orantinib in combination with transcatheter arterial chemoembolization (TACE) versus placebo in combination with TACE in patients with unresectable…
- Trial name
- ORIENTAL (NCT01465464)
- Testing
- Orantinib (TSU-68)
- Where
- 6 sites in Japan, South Korea and 1 more
- Volunteers
- 888 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Hepatocellular Cancer, AFP Expressing Tumors
AFPᶜ³³²T in Advanced HCC
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor.
- Trial name
- NCT03132792
- Testing
- Autologous genetically modified AFPᶜ³³²T cells
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 39 people
- Sponsor
- Adaptimmune
Hepatocellular Carcinoma, Liver Cirrhoses
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Hepatocellular Carcinoma (HCC) is a major health concern in the United States, particularly among people with liver cirrhosis. Out of every 100 patients with liver cancer, only 18 will survive 5 years or more.
- Trial name
- NCT03219372
- Testing
- Pravastatin Pill
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cedars-Sinai Medical Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01730937
- Testing
- Sorafenib, stereotactic body radiation therapy
- Where
- 51 sites in United States, Australia and 3 more
- Volunteers
- 193 people
- Sponsor
- Radiation Therapy Oncology Group
Liver Tumor, Liver Neoplasms
PET/CT-Assessment of Liver Tumor Ablation
In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or…
- Trial name
- NCT02018107
- Testing
- N-13 ammonia or F-18 fluorodeoxyglucose, PET scan
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Liver Cancer
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
The goal of this clinical research study is to test the accuracy of magnetic resonance elastogram (MRE) and 2-point dixon magnetic resonance imaging (2PD MRI) using new computer software (called "phase correction algorithm") in…
- Trial name
- NCT00543777
- Testing
- Magnetic Resonance Elastogram, 2-Point Dixon Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
IMC-A12 in Treating Patients With Advanced Liver Cancer
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00639509
- Testing
- cixutumumab, computed tomography, contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of the Liver, Liver Cancer
NOLA (NeuWave Observational Liver Ablation) Registry
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
- Conditions
- Cancer of the Liver, Liver Cancer, Neoplasms, Liver
- Trial name
- NCT04107766
- Testing
- Microwave Ablation
- Where
- 28 sites in United States, China and 6 more
- Volunteers
- 1,254 people
- Sponsor
- Ethicon, Inc.